Literature DB >> 22843911

Tumor angiogenesis in 75 cases of pleomorphic carcinoma of the lung.

Yukari Tsubata1, Akihisa Sutani, Tamio Okimoto, Motoki Matsuura, Isao Murakami, Ryousuke Usuda, Tsuneo Okumichi, Sei-Ichi Kakegawa, Kenichi Togashi, Shinji Kosaka, Yoshinori Yamashita, Koji Kishimoto, Takashige Kuraki, Takeshi Isobe.   

Abstract

BACKGROUND: Pleomorphic carcinoma (PC) of the lung is a rare tumor that usually has an aggressive clinical course and a poor prognosis. In this study, 75 cases of PC were reviewed to identify its clinical features, and we examined the expression of angiogenic factors. PATIENTS AND METHODS: We immunohistochemically examined the expression of angiogenic factors in tissue specimens of PC.
RESULTS: 66 males and 9 females were examined. The median survival time was 16.5 months. The stage and symptomatical diagnosis were significantly associated with the survival. In the immunohistochemical analyses, vascular endothelial growth factor (VEGF) was expressed in many cases of PC. A high score for angiogenesis was significantly related to a poorer prognosis.
CONCLUSION: We conclude that PC should be considered an aggressive disease, and that the stage and symptomatical diagnosis are strong prognostic factors. Furthermore, tumor angiogenesis provides significant prognostic information about the clinical outcome in PC.

Entities:  

Mesh:

Year:  2012        PMID: 22843911

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  5 in total

1.  Clinicopathological factors influenced the prognosis of surgically resected pulmonary pleomorphic carcinoma.

Authors:  Katsuhiro Okuda; Risa Oda; Ayumi Suzuki; Tadashi Sakane; Osamu Kawano; Hiroshi Haneda; Satoru Moriyama; Ryoichi Nakanishi
Journal:  J Thorac Dis       Date:  2017-05       Impact factor: 2.895

2.  Perioperative change in neutrophil-to-lymphocyte ratio (NLR) is a prognostic factor in patients with completely resected primary pulmonary sarcomatoid carcinoma.

Authors:  Yong Won Seong; Sung Joon Han; Woohyun Jung; Jae Hyun Jeon; Sukki Cho; Sanghoon Jheon; Kwhanmien Kim
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

3.  Clinicopathological Analysis of 17 Surgically Resected Pulmonary Pleomorphic Carcinoma Cases.

Authors:  Yoshihito Iijima; Yuki Nakajima; Hiroyasu Kinoshita; Yu Nishimura; Toshihiko Iizuka; Hirohiko Akiyama; Tomomi Hirata
Journal:  Ann Thorac Cardiovasc Surg       Date:  2020-06-03       Impact factor: 1.520

4.  Effective combined therapy with ramucirumab for advanced pulmonary pleomorphic carcinoma.

Authors:  Naoya Nishioka; Yoshiko Kaneko; Tadaaki Yamada; Naoko Okura; Soichi Hirai; Koichi Takayama
Journal:  Respirol Case Rep       Date:  2018-09-28

5.  A case of PD-L1 negative advanced pulmonary sarcomatoid carcinoma effectively treated with atezolizumab, carboplatin, paclitaxel, and bevacizumab.

Authors:  Kosuke Sawatari; Motohiro Izumi; Risa Sone; Tsuyoshi Hattori; Akira Sugimoto; Yosuke Eguchi; Takashi Mamoto
Journal:  Respir Med Case Rep       Date:  2022-01-04
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.